Clinical Extrapolation Report

Urolithin A: The Plateau Effect

Beyond 1000 mg daily, urolithin A supplementation hits hard pharmacokinetic ceilings — intestinal transporter saturation, hepatic conjugation bottlenecks, and renal clearance overflow. This interactive report visualizes why more is not better.

Read the full Urolithin A research →

Optimal Dosage

500–1000mg

Evidence-based therapeutic range

Mitophagy Activation

82–100%

Within the optimal dose band

Diminishing Return Point

>1000mg

Marginal gains plateau sharply

The Mitophagy Plateau

Mitophagy activation follows a classic dose-response curve that asymptotes near 1000 mg. Doubling the dose beyond that yields less than 5% additional activation.

Key Insight: The curve reaches 82% activation at 500 mg and 100% at 1000 mg — a diminishing marginal return of only 18 percentage points for doubling the dose. Beyond 1000 mg, each additional 500 mg adds ≤3 points.

Comparative Efficacy by Dosage Tier

Five dosage tiers compared: placebo baseline through saturated dose. The clinical step-up from 500 mg to 1000 mg is meaningful; from 1000 mg to 1500 mg, it's negligible.

Cost vs. Efficacy Dynamics

Bubble radius represents relative monthly cost. At 1500 mg+, cost scales linearly while efficacy flatlines — the very definition of diminishing returns.

The Absorption Bottleneck

Why excess urolithin A cannot be utilized — four sequential rate-limiting checkpoints.

Ingestion
UA enters the GI tract and is absorbed by enterocytes
↓
Epithelial Saturation
Intestinal transporter proteins reach capacity at ~500mg
↓
Hepatic Processing
Liver conjugation enzymes (UGTs) become rate-limiting
↓
The Plateau
Excess UA is excreted unmetabolized — no additional benefit

Optimized Protocol Recommendations

Standard Maintenance

500 mg / day

Achieves ~82% peak mitophagy activation. Optimal cost-to-benefit ratio for long-term daily supplementation. Well within transporter capacity.

Advanced Clinical

1000 mg / day

Reaches ~100% activation ceiling. Justified for targeted therapeutic goals. Beyond this, additional UA provides negligible mitophagic benefit.

Continue Your Research

Full UA White Paper

Biosynthesis, immunometabolism, neuroprotection, pharmacokinetics, and safety data.

Read White Paper →

UA Clinical Data Visual

Interactive charts of muscle endurance, inflammation biomarkers, and ATP production.

View Infographic →

NMN Ingredient Guide

Everything about NMN — clinical evidence, dosage, safety, and NAD⁺ elevation.

Learn About NMN →

Data visualizations are based on published clinical trial results and extrapolated dose-response models. For educational purposes. This content does not constitute medical advice. Mt. Angel Vitamins does not manufacture or sell urolithin A supplements.

†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.